{
  "pmcid": "10364515",
  "sha256": "d9c7fa8384252b0171c233a42fabc918e7b39c24c23d80dda62f416183a5ad6e",
  "timestamp_utc": "2025-11-09T21:53:17.219326+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.698239675016929,
    "reading_ease": 36.25751974723542,
    "word_count": 211
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: SAPTAP Trial: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This multicentre, non-inferiority randomised controlled trial (RCT)"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults with symptomatic chronic venous disease, recruited from seven medical centres in the Netherlands."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to SAP or TAP"
      },
      "Objective": {
        "score": 1,
        "evidence": "aimed to determine if single ambulatory phlebectomy with or without delayed endovenous truncal ablation (SAP) is non-inferior to thermal endovenous ablation with concomitant phlebectomy (TAP)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the VEINES-QOL/Sym score at 12 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "randomised to SAP or TAP using an automated service, with allocation concealment."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was not feasible for patients or clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between January 2015 and December 2018, 464 patients were randomised (SAP 227, TAP 237)."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was intention-to-treat."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "VEINES-QOL scores were 52.7 (95% CI 51.9 to 53.9) for SAP and 53.8 (53.3 to 55.1) for TAP."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were minor and similar between groups."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NTR 4821."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by Erasmus Medical Centre Rotterdam."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}